Cargando…
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809273/ https://www.ncbi.nlm.nih.gov/pubmed/36605207 http://dx.doi.org/10.3389/fimmu.2022.1110388 |
| _version_ | 1784863086037958656 |
|---|---|
| author | Kobayashi, Roger H. Gupta, Sudhir Melamed, Isaac Mandujano, J. Fernando Kobayashi, Ai Lan Ritchie, Bruce Geng, Bob Atkinson, Thomas Prescott Rehman, Syed Turpel-Kantor, Eva Litzman, Jiří |
| author_facet | Kobayashi, Roger H. Gupta, Sudhir Melamed, Isaac Mandujano, J. Fernando Kobayashi, Ai Lan Ritchie, Bruce Geng, Bob Atkinson, Thomas Prescott Rehman, Syed Turpel-Kantor, Eva Litzman, Jiří |
| author_sort | Kobayashi, Roger H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9809273 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98092732023-01-04 Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies Kobayashi, Roger H. Gupta, Sudhir Melamed, Isaac Mandujano, J. Fernando Kobayashi, Ai Lan Ritchie, Bruce Geng, Bob Atkinson, Thomas Prescott Rehman, Syed Turpel-Kantor, Eva Litzman, Jiří Front Immunol Immunology Frontiers Media S.A. 2022-12-20 /pmc/articles/PMC9809273/ /pubmed/36605207 http://dx.doi.org/10.3389/fimmu.2022.1110388 Text en Copyright © 2022 Kobayashi, Gupta, Melamed, Mandujano, Kobayashi, Ritchie, Geng, Atkinson, Rehman, Turpel-Kantor and Litzman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Kobayashi, Roger H. Gupta, Sudhir Melamed, Isaac Mandujano, J. Fernando Kobayashi, Ai Lan Ritchie, Bruce Geng, Bob Atkinson, Thomas Prescott Rehman, Syed Turpel-Kantor, Eva Litzman, Jiří Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title | Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title_full | Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title_fullStr | Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title_full_unstemmed | Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title_short | Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| title_sort | corrigendum: clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (octanorm [cutaquig(®)]) in the treatment of patients with primary immunodeficiencies |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809273/ https://www.ncbi.nlm.nih.gov/pubmed/36605207 http://dx.doi.org/10.3389/fimmu.2022.1110388 |
| work_keys_str_mv | AT kobayashirogerh corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT guptasudhir corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT melamedisaac corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT mandujanojfernando corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT kobayashiailan corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT ritchiebruce corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT gengbob corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT atkinsonthomasprescott corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT rehmansyed corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT turpelkantoreva corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies AT litzmanjiri corrigendumclinicalefficacysafetyandtolerabilityofanewsubcutaneousimmunoglobulin165octanormcutaquiginthetreatmentofpatientswithprimaryimmunodeficiencies |